SCHEMBL87330

SCHEMBL87330

CC[C@@H](C(=O)O)n1cnc2ccc(Cl)cc2c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 1/20 0.48
USP5 P45974 1/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 2/20 0.46
HTT P42858 2/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77994 1.00 GCK (0.48) GCKUSP5LMNAGAAMAPK1
SCHEMBL78872 0.85 FFAR1 (0.43) GCKUSP5LMNAGAAMAPK1
SCHEMBL78194 0.85 GAA (0.48) GCKLMNAGAAMAPK1HTT
SCHEMBL79350 0.85 HPGD (0.44) GCKUSP5LMNAGAAMAPK1
SCHEMBL92948 0.84 GAA (0.48) GCKLMNAGAAMAPK1KDM4E
SCHEMBL80194 0.83 USP5 (0.68) GCKUSP5LMNAKDM4EHPGD
SCHEMBL311956 0.83 USP5 (0.68) GCKUSP5LMNAKDM4EHPGD
SCHEMBL78294 0.81 DDR1 (0.47) USP5HPGDTSHR
SCHEMBL80119 0.81 DDR1 (0.47) USP5HPGDTSHR
SCHEMBL12569598 0.80 CASP3 (0.43) GCKGAAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129381-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8129381-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-12 US disclosed
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-12 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
US-7553852-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-30 US disclosed
CN-100503572-C Caspase inhibitors and uses thereof VERTEX PHARMA (US) 2009-06-24 CN disclosed
CN-1675184-A Caspase inhibitors and uses thereof VERTEX PHARMA (US) 2005-09-28 CN disclosed
WO-2004002961-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281128-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 GCK 2704/4885USP5 590/4885LMNA 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.